Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis

Scalp and nail psoriasis have a major impact on quality of life and are traditionally resistant to therapy. Ixekizumab is a monoclonal antibody that targets IL‐17A, a key cytokine in psoriasis pathogenesis.

[1]  M. Sundaram,et al.  Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  M. Pasch,et al.  Nail Psoriasis, the unknown burden of disease , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  A. Gottlieb,et al.  Secukinumab improves hand, foot and nail lesions in moderate‐to‐severe plaque psoriasis: subanalysis of a randomized, double‐blind, placebo‐controlled, regimen‐finding phase 2 trial , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  M. Lebwohl,et al.  A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. , 2014, Journal of the American Academy of Dermatology.

[5]  Y. Wasfi,et al.  Ustekinumab improves nail disease in patients with moderate‐to‐severe psoriasis: results from PHOENIX 1 , 2014, The British journal of dermatology.

[6]  D. Sotiriadis,et al.  Biologic agents in nail psoriasis: efficacy data and considerations , 2013, Expert opinion on biological therapy.

[7]  A. Patrizi,et al.  A 36‐week retrospective open trial comparing the efficacy of biological therapies in nail psoriasis , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[8]  E. Berardesca,et al.  A 24‐week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis , 2013, The British journal of dermatology.

[9]  M. Augustin,et al.  Nail psoriasis – a treatment challenge , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[10]  S. Tyring,et al.  Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. , 2012, Journal of the American Academy of Dermatology.

[11]  Subhashis Banerjee,et al.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. , 2012, The New England journal of medicine.

[12]  M. Alsina-Gibert,et al.  Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy) , 2011 .

[13]  K. Papp,et al.  Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. , 2011, Archives of dermatology.

[14]  U. Mrowietz,et al.  Psoriasis des behaarten Kopfes , 2011 .

[15]  K. Reich,et al.  Nail psoriasis as a severity indicator: results from the PsoReal study , 2010, Patient related outcome measures.

[16]  K. Reich,et al.  Nail psoriasis in Germany: epidemiology and burden of disease , 2010, The British journal of dermatology.

[17]  J. Saurat,et al.  Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial , 2010, Dermatology.

[18]  S. Yaemsiri,et al.  Growth rate of human fingernails and toenails in healthy American young adults , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[19]  K. Peris,et al.  Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial , 2009, Archives of drug information.

[20]  J. Lambert,et al.  Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate‐to‐severe psoriasis , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  J. Gelfand,et al.  The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. , 2009, Journal of the American Academy of Dermatology.

[22]  G. Wozel.  Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. , 2008, Clinics in dermatology.

[23]  F. Nestle,et al.  Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. , 2008, Journal of the American Academy of Dermatology.

[24]  K. Kragballe,et al.  Scalp psoriasis: a review of current topical treatment options , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.

[25]  Richard K Scher,et al.  Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. , 2003, Journal of the American Academy of Dermatology.

[26]  P. C. van de Kerkhof,et al.  Scalp Psoriasis, Clinical Presentations and Therapeutic Management , 1998, Dermatology.

[27]  B. Thiers.  Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study , 2009 .

[28]  P. Kerkhof,et al.  Psoriasis of the Scalp , 2001 .

[29]  P. C. van de Kerkhof,et al.  Psoriasis of the scalp. Diagnosis and management. , 2001, American journal of clinical dermatology.

[30]  P. V. D. van de Kerkhof,et al.  Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. , 1996, Dermatology.

[31]  A. S. Boyd.  Scalp psoriasis. , 1988, American family physician.